| Description |
Recombinant Human CD58 Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Phe29-Arg215. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
AAH05930 |
| Target Symbol |
CD58 |
| Synonyms |
Lymphocyte function-associated antigen 3；Ag3；CD58；LFA3 |
| Species |
Human |
| Expression System |
HEK293 |
| Tag |
C-hFc |
| Expression Range |
Phe29-Arg215 |
| Mol. Weight |
The protein has a predicted MW of 48.1 kDa. Due to glycosylation, the protein migrates to 65-75 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Activity |
The affinity constant of 15.48 nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
Loss of CD58 is a common mechanism for tumor immune evasion in lymphoid malignancies. CD58 loss is known to occur due to both genetic and non-genetic causes; therefore, we hypothesized that restoring CD58 expression in lymphoma cells may be an effective treatment approach. EZH2 is involved in the epigenetic silencing of CD58 in lymphoma cells as a mechanism for tumor immune escape, and EZH2 inhibitors are able to restore epigenetically suppressed CD58 expression. |
